1207754-99-1

Basic information

• Product Name: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate
• Synonyms: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate;tert-butyl (2R)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate;(2R)-1-Boc-2-methylpyrrolidine-2-methanol
• CAS NO: 1207754-99-1
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Mol File: 1207754-99-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 293.8±13.0 °C(Predicted)
• Appearance: /
• Density: 1.055±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(1207754-99-1)
• EPA Substance Registry System: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(1207754-99-1)

Safety Data

• Hazardous Substances Data: 1207754-99-1(Hazardous Substances Data)

Usage

General Description

(R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate is a chemical compound in the category of pyrrolidines, which are a class of organic chemical compounds that contain a pyrrolidine ring. The '(R)' in its name indicates the configuration of its chiral center, which means it has a unique three-dimensional arrangement of the atoms attached to its central carbon atom. (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate has a tert-butyl ester group (tert-butyl carboxylate), a functionality often used in medicinal chemistry due to its increased stability compared to other esters. Other key features include a hydroxymethyl group (-CH2OH) and a methyl group (-CH3) attached to the second carbon of the pyrrolidine ring. The specific chemical and physical properties, such as melting point, boiling point, or solubility, will depend on the exact conditions like temperature and pressure. Its potential uses, biological activity, and toxicity are not specified and would likely need to be determined experimentally.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 63399-77-9 (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure 
• 166170-15-6 (R)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid 
• 619307-07-2 (R)-N-(tert-butoxycarbonyl)-α-methylproline ethyl ester 

Downstream Products

• 1407975-86-3 C₅₆H₇₉N₅O₇ 
• 1407975-85-2 C₂₁H₂₈F₃NO₅ 
• 1207755-00-7 1,1-dimethylethyl (2R)-2-methyl-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase

Orally bioavailable inhibitors of β-(1,3)-d-glucan synthase have been pursued as new, broad-spectrum fungicidal therapies suitable for treatment in immunocompromised patients. Toward this end, a collaborative medicinal chemistry program was established based on semisynthetic derivatization of the triterpenoid glycoside natural product enfumafungin in order to optimize in vivo antifungal activity and oral absorption properties. In the course of these studies, it was hypothesized that the pharmacokinetic properties of the semisynthetic enfumafungin analog 3 could be improved by tethering the alkyl groups proximal to the basic nitrogen of the C3-aminoether side chain into an azacyclic system, so as to preclude oxidative N-demethylation. The results of this research effort are disclosed herein.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.